一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Lazertinib；Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)；Amivantamab Intravenous，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长春、常州、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Lazertinib；Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)；Amivantamab Intravenous · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Shijitan Hospital, Capital Medical University · 北京
- Beijing Friendship Hospital Capital Medical University · 北京
- Peking University Third Hospital · 北京
- Beijing Chest hospital, Capital medical university · 北京
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Jilin cancer hospital · 长春
- The First People's Hospital Of Changzhou · 常州
- Sichuan Cancer Hospital · 成都
- West China Hospital Sichuan University · 成都
- Chongqing University Cancer Hospital · 重庆
- Southwest Hospital · 重庆
- First Affiliated Hospital of Gannan Medical University · Ganzhou
- Sun Yat-Sen Memorial Hospital Sun Yat-sen University · 广州
- The First Affiliated Hospital Sun Yat sen University · 广州
- The Second Affiliated Hospital of Zhejiang University College of Medicine · 杭州
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin medical university cancer hospital · 哈尔滨
- Huizhou Municipal Central Hospital · 惠州
- Huizhou First Hospital · 惠州
- Liuzhou people's Hospital · 柳州
- Affiliated Hospital of North Sichuan Medical College · 南充
- Fudan University Shanghai Cancer Center · 上海
- Shengjing Hospital Of China Medical University · 沈阳
- Shenzhen People s Hospital · 深圳
- Shenzhen university General Hospital · 深圳
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology · 武汉
- The First Affiliated Hospital of Xian Jiaotong University · 西安
- Xiangyang Central Hospital · 襄阳
- Yantai Yuhuangding Hospital · 烟台
- Henan Cancer Hospital · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Have histologically or cytologically confirmed, advanced or metastatic non-small cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by an Food and Drug Administration (FDA)-approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United Started \[US\]) or an accredited local laboratory (sites outside of the US)
- * Have progressed on or after osimertinib (or another approved 3rd generation epidermal growth factor receptor \[EGFR\] tyrosine kinase inhibitor \[TKI\]) and platinum-based chemotherapy (irrespective of order). a) The 3rd generation EGFR TKI must have been administered as the first EGFR TKI for metastatic disease or as the second TKI after prior treatment with first- or second-generation EGFR TKI in participants with metastatic EGFR T790M mutation positive NSCLC. b) Participants who decline or are otherwise ineligible for chemotherapy may be enrolled after discussion with the medical monitor. c) Any adjuvant or neoadjuvant treatment, whether with a 3rd generation EGFR TKI or platinum based chemotherapy, would count towards the prior treatment requirement if the participant experienced disease
- * Have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) version 1.1
- * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
- * Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia \[any grade\], Grade less than or equal to (\<=) 2 peripheral neuropathy, and Grade \<=2 hypothyroidism stable on hormone replacement)
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05388669；登记信息更新于 2026-09-28；本站同步于 2026-10-08。